S1173 Efficacy and Safety of Interleukin-12, 23 Inhibitors vs Interleukin-23 inhibitors for Moderate to Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis

Ravi Teja Pasam,Misha Gautam,Sruthi Venugopalan,Babu Mohan,Udaykumar Navaneethan
DOI: https://doi.org/10.14309/01.ajg.0001034060.34136.5b
2024-10-26
The American Journal of Gastroenterology
Abstract:Interleukin 23 (IL-23) inhibitors have been shown to have superior efficacy compared to interleukin - 12, 23 (IL-12,23) inhibitors in patients with psoriasis. It is unclear whether this translates to patients with moderate to severe ulcerative colitis (UC). A systematic review and network meta-analysis (NMA) of clinical drug trials was performed to answer this question.
gastroenterology & hepatology
What problem does this paper attempt to address?